Analyzing Audi's Controversial Super Bowl Commercial
If you haven’t seen Audi’s #DriveProgress Big Game Commercial – “Daughter” from the super bowl check it out (click the image above). It gets into the hearts and minds of anyone who watches it.
Regardless if it warms your heart or angers it, you’re sure to have some reaction. If it helps you see a brighter future for the young women of the world or it frustrates you, it’s likely started some thoughts and maybe even some discussions.
The early viewer feedback wasn’t positive. Some YouTube viewers calling the wage gap between men a “myth” and others looking at the overall theme as negative. Some commenters even called this commercial “feminist propaganda”.
Viewers of the commercial also jumped to action on Twitter to point out that Audi’s board of directors is full of men and that the US equal pay act was passed in 1963.
Whether you agree with the commercial or not, the question we’re asking is why?
Why did Audi choose to produce this commercial and pay millions of dollars to run it during the Super Bowl? What were the intentions behind this controversial commercial? Audi could have kept it simple, followed the “norm” producing a typical “our car is the best” commercial as they have in the past. They made a choice, a decision they knew would be a controversial one. Based on the social media comments and media feedback we’ve looked at six possible intentions behind Audi producing this commercial.
The definition of propaganda found on Wikipedia refers to several key characteristics. These areas include biased or misleading nature, used to promote a political cause or point of view, is used primarily to influence an audience and further an agenda, often by presenting facts selectively. Unarguably the commercial is biased towards women’s pay equality. It could be argued that it does promote a political cause. The true “guts” of a propaganda message is around misleading presenting facts selectively. Was Audis’ goal to mislead its viewers? Considering that there is no data presented, no stats or measurements within the commercial it does not mislead with selective facts. Was Audi misleading their audience into believing they are committed to equal pay when they are not? What win could this commercial have if that was their intention? It’s obvious this would stir up discussion inside and outside the company. Equal pay is subjective. Without total performance and pay transparency employees will be in the dark, or at least the shadows, when comparing their pay to others. No doubt there were several employees that approached their manager, HR or someone else in the organization after this commercial was launched online. Requests for raises, discussions or evaluations of pay. The idea that Audi wants to mislead the public about their commitment to this has no legs. Publishing this type of commercial no doubt created additional work for those managers, HR representatives and others within the organization. From this perspective, it wasn’t in Audi’s best interest. Unless, they wanted more women within their company to speak up, ask questions about pay equality and challenge it. If this was their intention would it be so bad?
What if Audi’s reasons for producing this commercial were political? As a way of “lobbying” for equal pay across the US. As a friendly Twitter user pointed out, the equal pay act in the US was passed in 1963, thus voiding a portion of the political argument. Could Audi want improved oversight, regulation and enforcement from the government? It’s possible, if they are already committed to equal pay, this would be welcomed. Creating parity across automotive companies with regards to equal pay implementation would be a negative for Audi. They wouldn’t have the competitive advantage. As well, an increased focus on enforcing equal pay would cost Audi with implementing changes. It’s reasonable to assume that this was not Audi’s intention.
Sell More Cars to Women
The purpose of advertising is to sell a product or service. It’s logical and reasonable to assume that this heartfelt, emotionally charged and controversial ad, was created to simply sell more cars. Focusing on women as a target market is not new for Audi. Last year, they ran a commercial that focused on gender equality with children’s toys and women driving. With a slogan “Playing, just like driving, shouldn’t be a matter of gender”. Audi has their sights on Women as a target market currently. It shouldn’t be surprising if a car companies’ intention to create a new commercial was simply to sell more cars.
Hold Themselves Accountable
We’ve all heard of various forms of public accountability. Many people post their weight loss goals and workout routine on social media to hold themselves accountable. Others find an accountability buddy to hold their feet to the fire. A public statement like “Audi of America is committed to equal pay for equal work” is one that holds them accountable. If their intention was to hold themselves accountable, I’d say they have achieved their goal.
Bring Light to Pay Equality
What would be so bad if Audi intention was to shed light on pay equality? Nothing, unless there isn’t a problem. If there is not an equal pay problem, we end up back to the concept that this commercial was propaganda. Is there an equal pay issue? Last year I wrote about women equality from the opposite point of view of my personal opinion (you can read this here). What this helped me to understand is that we can frame data in a way that supports either position. We can drop data that we don’t agree with, while still staying truthful and highlight data towards our opinion. Despite a desperate attempt to disprove the inequality of women in the workforce, I couldn’t. Through the numerous research studies that I could locate, they all pointed to one truth; women are not treated equally in the workplace. If you don’t believe me, check out McKinsey & Company’s Women in the Workplace study. If we conclude this research is accurate, once again we move out of the propaganda territory. If Audi’s sole purpose for producing this commercial was to promote pay equality for women, whether you believe it’s true or not, is this bad? If they produced a commercial that stated “Audi of America is committed to children living a happy life” we wouldn’t be questioning it. If you believed that all children are happy already, would this type of commercial be frowned on?
Enroll Intelligent, Driven Women into Their Brand
When I first watched the commercial, my head went directly to recruiting. In our ConvertiHire training program, we encourage leaders to enroll candidates. Enroll candidates into the mission and vision of their business. Audi’s intention could be to enroll smart and driven women into their organization. A megaphone if you will, to let women know that Audi shares a value that many of them may also value. If this is Audi’s intention, what a great one.
Regardless of what you believe Audi’s intention was, I hope that you see this as an opportunity for discussion within your home and the company that you work for. Any company that discusses equality in the workplace and any organization that has this as a priority is on the right track to create a work environment that benefits everyone.
How We're Investing in the Search for a Cancer Cure
Written by: Frank Jennings, Ph.D., Portfolio Manager
I hate cancer.
I’ve lost one too many friends to this insidious disease and I’ve made it a priority to be part of the effort to find a cure for it. Every day, I draw motivation from the people I’ve lost in my work as Portfolio Manager of Oppenheimer Global Opportunities Fund.
I may not be a doctor or medical industry professional, but the work my team and I do has brought us to the front lines of the ongoing fight against cancer. The Fund’s guiding philosophy is to invest in emergent growth companies that we believe have the potential to grow into large, highly profitable businesses.
Our search for these types of companies has given me renewed hope that we are closer than ever to finding a cure for one of the deadliest scourges humanity has ever known.
OppenheimerFunds’ Role in the Fight
Oppenheimer Global Opportunities Fund invests in a number of pharmaceutical and biotechnology companies that are developing breakthrough drugs that can potentially treat the disease more effectively without debilitating side effects, make it easier for patients to manage pain, and possibly even lower the cost of treatment.
The cutting-edge therapies that are in development may even pave the way to the ultimate goal – a cure for all forms of the disease. Of course, one glance at the National Cancer Institute (NCI) website is all it takes to remind us we’re in a fight that often feels like an uphill race against time.
At some point in their lifetime, nearly 40% of the population will be diagnosed with cancer, according to the NCI. Last year in the United States alone, 1.7 million people received this dreaded news from their doctor, while nearly 600,000 people succumbed to the disease.1
These statistics certainly make it fair to ask why I’m so optimistic about the future of cancer treatment and the potential for a cure.
Well for starters, just consider that geneticists have finally mapped the entire human genome. Today, 100 million people have had their genomes mapped, which has enabled us to confirm, for example, that there is a particular gene mutation that places some women at a high risk of developing breast or ovarian cancer at some point in their life.
This is important on several fronts. First, it allows doctors to know beforehand whether or not a cancer drug will work on a patient due to the genetic makeup of the cancer. This means fewer drugs will be prescribed inappropriately. It may even help bring promising new treatments to market faster.
By knowing a cancer’s genetic makeup, drug trials can be conducted only on people with a high probability of success. In turn, this will result in less money wasted, better outcomes for patients, and ultimately, faster approvals by the U.S. Food and Drug Administration (FDA) and other international regulatory bodies.
The Biotechnology and Pharmaceutical Companies We Believe In
One of the largest holdings in the portfolio is in a company that develops and markets therapies that mimic a person’s own immune system to fight cancer. This particular company, which is headquartered in the U.S., recently developed a new antibody-drug conjugate (ADC) technology that allows its medications to attack cancer cells with fewer side effects than chemotherapy.
This firm has a number of innovative cancer medications at its disposal – including therapies for treating various types of lymphoma. The company continues to sign partners onto its proprietary ADC technology, and we believe it is well-positioned to earn millions in royalties over the long term, making it an attractive acquisition target for larger drug makers.
There are a number of European pharmaceutical and biotech firms in the portfolio as well, including another company that specializes in immunotherapy – which seeks to boost the body’s immune system to fight off cancer.
Analysts have predicted this company’s treatment for multiple myeloma has blockbuster potential. And although the drug is primarily used to fight blood cancer, there are signs that it could also work against solid tumors as well. Now beyond the “cash-burning stage” that afflicts most drug makers at some point, this company is on track to becoming a mature biotech firm that’s positioned for strong overall sales and steady royalty income in the near future.
Over the last five years, shares of this company have climbed more than 2,000% and we see potential for continued strong future growth.
How the Cancer Fight Aligns with My Investment Philosophy
I believe companies have a lifecycle – just like people do. There’s a beginning, adolescence, prime years, and an eventual decline phase. Companies usually begin as entrepreneurial ventures powered by the spirit of a startup. If they’re successful, they gradually mature into corporate entities and can enjoy an extended run of success. The decline phase typically takes root when companies get too big and bogged down by bureaucracy, regulation and saturated markets.
The Fund seeks to invest in businesses that still have exponential growth ahead of them. I’ve been excited to discover that there are quite a few companies like this at the forefront of the fight against cancer. Investing in these types of companies within the Oppenheimer Global Opportunities Fund can help clients achieve their desired investment outcomes, which is my top priority as a portfolio manager.
Combining this core mission with my personal desire to see cancer eradicated is one of the most gratifying parts of my job.
Learn more about how we think about investments differently, visit challengetheindex.com
Foreign investments may be volatile and involve additional expenses and special risks, including currency fluctuations, foreign taxes, regulatory and geopolitical risks. Emerging and developing market investments may be especially volatile. Eurozone investments may be subject to volatility and liquidity issues. Investments in securities of growth companies may be volatile. Mid-sized company stock is typically more volatile than that of larger company stock. It may take a substantial period of time to realize a gain on an investment in a mid-sized company, if any gain is realized at all. Fixed income investing entails credit and interest rate risks. When interest rates rise, bond prices generally fall, and the Fund’s share prices can fall. Below-investment-grade (“high yield” or “junk”) bonds are more at risk of default and are subject to liquidity risk. Diversification does not guarantee profit or protect against loss.
Mutual funds and exchange traded funds are subject to market risk and volatility. Shares may gain or lose value.
These views represent the opinions of OppenheimerFunds, Inc. and are not intended as investment advice or to predict or depict the performance of any investment. These views are as of the publication date, and are subject to change based on subsequent developments.
Carefully consider fund investment objectives, risks, charges, and expenses. Visit oppenheimerfunds.com or call your advisor for a prospectus with this and other fund information. Read it carefully before investing.
OppenheimerFunds is not affiliated with IRIS.xyz.
©2017 OppenheimerFunds Distributor, Inc.
- 1 of 1888